IMU's subsidiary CHM has an advanced AML - treatment currently in a ph1b study with MD Anderson Texas and it is expected to turn into a registrational trial after that.
Hopper got almost everything covered, attacking liquid cancers with CAR-T ( IMU, CHM ), all solid cancer with an OV ( IMU ) and some with the B-cell vaccines, most gastric types with CDH 17 CAr-T ( CHM ) plus the latest radio isotopes ( RAD ) that get attached to solid cancer cells only and then, by using radiation, starting the kill.
Most advanced IMU's Acer-Cel and CHM's GBM CAR-T as well as AML-NK-CAR-T.
If any, which one gets over the line first and will the funding be sufficient until then. These are the big unknowns.
GLTA
Media Thread, page-15053
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
